Analystreport

Aptose Biosciences Inc. (NASDAQ: APTO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock, down previously from $8.50.

Aptose Biosciences, Inc. - Common Shares  (APTO) 
Last aptose biosciences, inc. - common shares earnings: 3/10 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: aptose.com/investors